findmyKOL

Courtney DiNardo, MD

Enriched profile

Professor, Department of Leukemia, Division of Cancer Medicine · The University of Texas MD Anderson Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2021–2026

Courtney DiNardo is Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,656 publications with 49,719 citations (h-index 96); ClinicalTrials.gov lists 24 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Courtney DiNardo as a Highly Cited Researcher (Clinical Medicine, 2021-2024).

Data verified 25 Aug 2026

Overview

Updated 14 Oct 2026

Courtney D. DiNardo, MD, is Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,656 publications with 49,719 citations (h-index 96), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 32 companies, 4 NIH-funded awards (2021–2026).

  • Most recent indexed publication: 2026 · Blood advances
  • Top research focus: Acute Myeloid Leukemia Research
  • 24 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 32 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)20 trialsLeukemia, Myeloid, Acute14 trialsMDS / MPN9 trialsLeukemia, Biphenotypic, Acute2 trialsLeukemia, Lymphocytic, Chronic, B-Cell1 trialLeukemia, Lymphoid1 trialRecurrence1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trials7Industry payments66Publications60Tibsovogeneric · IvosidenibClinical trials3Industry payments32Publications7Onureggeneric · AzacitidineClinical trials6Industry payments7Publications22Xospatageneric · GilteritinibClinical trials1Industry payments12Publications2Idhifageneric · EnasidenibClinical trials3Industry payments2Publications5Rezlidhiageneric · OlutasidenibClinical trials3Industry payments14Publications—CytarabineClinical trials3Industry payments—Publications7DecitabineClinical trials3Industry payments—Publications7CladribineClinical trials1Industry payments—Publications5Hypomethylating AgentClinical trials1Industry payments—Publications5Revuforjgeneric · RevumenibClinical trials—Industry payments5Publications1IdarubicinClinical trials1Industry payments—Publications3

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trials—Industry payments48Servier Pharmaceuticals LLCClinical trials—Industry payments26Genentech USA, Inc.Clinical trials—Industry payments23Celgene CorporationClinical trials—Industry payments21M.D. Anderson Cancer CenterClinical trials21Industry payments—Astellas Pharma US IncClinical trials—Industry payments16Rigel Pharmaceuticals, Inc.Clinical trials—Industry payments14Daiichi Sankyo Inc.Clinical trials—Industry payments12Gilead Sciences, Inc.Clinical trials—Industry payments8GlaxoSmithKline, LLC.Clinical trials—Industry payments8Nippon Shinyaku Co.,LtdClinical trials—Industry payments8Servier Affaires MedicalesClinical trials—Industry payments8AstraZeneca Pharmaceuticals LPClinical trials—Industry payments7Dr.Reddy's Laboratories,Inc.Clinical trials—Industry payments6E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments5Syndax Pharmaceuticals, Inc.Clinical trials—Industry payments5Eli Lilly and CompanyClinical trials—Industry payments4Agios Pharmaceuticals, Inc.Clinical trials—Industry payments3Genmab U.S., Inc.Clinical trials—Industry payments3Jazz Pharmaceuticals Inc.Clinical trials—Industry payments3Novartis Pharmaceuticals CorporationClinical trials—Industry payments3BeiGene USA, Inc.Clinical trials—Industry payments2Amgen Inc.Clinical trials—Industry payments1AstraZeneca UK LimitedClinical trials—Industry payments1BeOne Medicines USA, Inc.Clinical trials—Industry payments1Eastern Cooperative Oncology GroupClinical trials1Industry payments—Genentech, Inc.Clinical trials—Industry payments1Genmab A/SClinical trials—Industry payments1Les Laboratoires ServierClinical trials—Industry payments1Lilly USA, LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,656publications

Distinct works indexed by OpenAlex, matched via ORCID; 284 in PubMed.

49,719citations

Total citations across indexed works.

96h-index

Hirsch index (OpenAlex). i10-index 519.

Clinical & industry

trials, payments and federal funding
24clinical trials

Investigator role on registered studies.

View trials ↓
32companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2021–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    67.5%
    Nucleoside Metabolic Inhibitor16%
    Inqovi100%
    Part D<11 patients
    Isocitrate Dehydrogenase 1 Inhibitor15.4%
    Tibsovo100%
    Part D<11 patients

    + 3 more classes in this area

  • Anti-infectives

    32.5%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.9%
    Valacyclovir100%
    Part D≥18 patients
    Fluoroquinolone Antibacterial13.6%
    Levofloxacin100%
    Part D≥14 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

4 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:

All 14 award records: search, sort and filter.Explore →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Tapan M. Kadia1046Hagop M. Kantarjian999Farhad Ravandi932Guillermo Garcia‐Manero928Naval Daver800Elias Jabbour731Gautam Borthakur684Marina Konopleva617Naveen Pemmaraju583Nicholas J. Short550Koji Sasaki473Guillermo Montalban‐Bravo427Sanam Loghavi418Koichi Takahashi383Jörge E. Cortes321Ghayas C. Issa316Musa Yılmaz296Nitin Jain292Yesid Alvarado284Michael Andreeff284Sherry Pierce282Keyur P. Patel256Kelly S. Chien220Rashmi Kanagal‐Shamanna218Naval Daver204Abhishek Maiti187Danielle Hammond179Prithviraj Bose169Lucia Masárová166Hussein A. Abbas163Guilin Tang160Steven M. Kornblau159Alexandre Bazinet159Jayastu Senapati158Kapil N. Bhalla151Maro Ohanian141Sa A. Wang137Zeev Estrov131William G. Wierda131Álex Bataller127

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/courtney-dinardo-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/profile/Courtney-Dinardo-2

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/runx1research/p/C90COY-qPKm

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • LinkedIn

    linkedin.com/posts/aacrjournals_courtney-d-dinardo-md-msce-recipient-activity-7364318192967548930-vOtl

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • LinkedIn

    linkedin.com/posts/blood-cancers-today_courtney-dinardo-discusses-first-in-human-activity-7054209342576738305-1sDh

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • LinkedIn

    linkedin.com/posts/mdandersoncancercenter_md-anderson-research-highlights-for-may-10-activity-7062169445036666881-LB6q

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • X / Twitter

    x.com/mdandersonnews/status/1293717662703509504

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Editor in Chief

    Translational Leukemia Research and Therapy

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    Editorial Review Board, American Journal of Hematology

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Section Editor

    Cancer

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Committee Member

    The Leukemia & Lymphoma Society Therapy Acceleration Program

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    Editorial Review Board, Blood

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    American Society of Hematology

    2009
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    American Society of Clinical Oncology

    2009
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    2021202220232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Associate Member

    The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Leader

    Hereditary Hematologic Malignancy Clinic (HHMC), MD Anderson (exact formal title uncertain -- AAMDSIF source describes her as having 'led to the development of' HHMC without stating a formal title …

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.